Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862496 | 0.86 | PTGES (0.41) | CYP1A2MAPTALDH1A1CYP2C19 | |
| SCHEMBL22558915 | 0.84 | KMT2A (0.41) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL29481131 | 0.83 | SMN1; SMN2 (0.41) | CYP1A2MAPTTDP1ALDH1A1POLB | |
| SCHEMBL1490855 | 0.83 | SMN1; SMN2 (0.41) | CYP1A2MAPTTDP1ALDH1A1POLB | |
| SCHEMBL3867800 | 0.83 | EGLN2 (0.39) | MAPTALDH1A1HPGD | |
| SCHEMBL22558817 | 0.81 | MAPT (0.44) | CYP3A4CYP1A2CYP2D6MAPTTDP1 | |
| SCHEMBL4527410 | 0.80 | MAPK1 (0.41) | CYP1A2MAPTTDP1ALDH1A1POLB | |
| SCHEMBL1486584 | 0.79 | MEN1 (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL3861961 | 0.76 | TNF (0.39) | — | |
| SCHEMBL6760464 | 0.75 | PTGES (0.43) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295970-B2 | Imidazoquinoline compounds and prodrugs thereof | UNIVERSITY OF KANSAS (US) | 2025-05-13 | — | — | US | disclosed |
| US-20220177472-A1 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | UNIVERSITY OF KANSAS (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220177472-A1 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | UNIVERSITY OF KANSAS (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2020214783-A1 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | UNIVERSITY OF KANSAS (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020214783-A1 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | UNIVERSITY OF KANSAS (US) | 2020-10-22 | — | — | WO | disclosed |
| US-6790961-B2 | REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6686472-B2 | Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6608201-B2 | Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-19 | — | — | US | disclosed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6348462-B1 | VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0872478-A2 | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0582581-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177472-A1 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | TLR7, TLR8, TLR1 | CYP3A4 1285/4885CYP1A2 1606/4885CYP2D6 2440/4885 |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | IFNAR1, IRF3, IFNG | CYP3A4 23/4885CYP1A2 306/4885CYP2D6 164/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | CYP3A4 101/4885CYP1A2 392/4885CYP2D6 420/4885 |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | UGT1A4, QARS1, HTR4 | CYP3A4 4/4885CYP1A2 110/4885CYP2D6 236/4885 |
| US-12295970-B2 | Imidazoquinoline compounds and prodrugs thereof | TLR7, TLR8, TLR1 | CYP3A4 1285/4885CYP1A2 1606/4885CYP2D6 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.